Elevance Health, Inc. (ELV)
NYSE: ELV · Real-Time Price · USD
294.95
-0.80 (-0.27%)
At close: Mar 18, 2026, 4:00 PM EDT
292.67
-2.28 (-0.77%)
After-hours: Mar 18, 2026, 7:04 PM EDT
Elevance Health Stock Forecast
Stock Price Forecast
The 17 analysts that cover Elevance Health stock have a consensus rating of "Buy" and an average price target of $383.65, which forecasts a 30.07% increase in the stock price over the next year. The lowest target is $297 and the highest is $485.
Price Target: $383.65 (+30.07%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Elevance Health stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 6 | 6 | 6 | 7 | 7 | 7 |
| Hold | 6 | 6 | 7 | 7 | 7 | 7 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 16 | 16 | 17 | 18 | 18 | 18 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Mizuho | Mizuho | Buy Maintains $413 → $350 | Buy | Maintains | $413 → $350 | +18.66% | Mar 11, 2026 |
| JP Morgan | JP Morgan | Buy Maintains $394 → $397 | Buy | Maintains | $394 → $397 | +34.60% | Feb 2, 2026 |
| Truist Securities | Truist Securities | Strong Buy Maintains $400 → $390 | Strong Buy | Maintains | $400 → $390 | +32.23% | Feb 2, 2026 |
| Barclays | Barclays | Buy Maintains $404 → $393 | Buy | Maintains | $404 → $393 | +33.24% | Jan 30, 2026 |
| Wells Fargo | Wells Fargo | Buy Maintains $424 → $391 | Buy | Maintains | $424 → $391 | +32.56% | Jan 30, 2026 |
Financial Forecast
Revenue This Year
195.93B
from 199.13B
Decreased by -1.61%
Revenue Next Year
202.00B
from 195.93B
Increased by 3.10%
EPS This Year
26.15
from 25.21
Increased by 3.74%
EPS Next Year
29.52
from 26.15
Increased by 12.87%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|
| High | 218.0B | 229.7B | ||
| Avg | 195.9B | 202.0B | ||
| Low | 183.3B | 190.4B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|
| High | 9.5% | 17.2% | ||
| Avg | -1.6% | 3.1% | ||
| Low | -8.0% | -2.8% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 29.42 | 33.62 | |||
| Avg | 26.15 | 29.52 | |||
| Low | 24.99 | 27.81 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 16.7% | 28.6% | |||
| Avg | 3.7% | 12.9% | |||
| Low | -0.9% | 6.3% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.